Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events

BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICIs) are used to treat several cancers, but they sometimes induce immune-related adverse events (irAEs). Patients with irAEs often have improved antitumor responses, but discontinuation of ICIs after irAEs is considered necessary. Resuming the use...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawahira, Machiko, Kanmura, Shuji, Mizuno, Keiko, Machida, Kentaro, Ohtsuka, Takao, Sato, Masami, Enokida, Hideki, Yamashita, Masaru, Kanekura, Takuro, Arima, Shiho, Nakamura, Norifumi, Sugiura, Tsuyoshi, Yoshimoto, Koji, Kobayashi, Hiroaki, Ishitsuka, Kenji, Suzuki, Shinsuke, Ueno, Shinichi, Ido, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049539/
https://www.ncbi.nlm.nih.gov/pubmed/35482642
http://dx.doi.org/10.1371/journal.pone.0267572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049539/
https://www.ncbi.nlm.nih.gov/pubmed/35482642
http://dx.doi.org/10.1371/journal.pone.0267572

Ejemplares similares